Amphastar Pharmaceuticals, Inc.
AMPH
$19.54
$0.542.84%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 719.89M | 723.76M | 720.74M | 725.71M | 712.81M |
| Total Other Revenue | -- | -455.00K | 1.94M | 4.95M | 19.15M |
| Total Revenue | 719.89M | 723.31M | 722.68M | 730.66M | 731.97M |
| Cost of Revenue | 363.83M | 366.27M | 362.35M | 361.65M | 358.11M |
| Gross Profit | 356.06M | 357.04M | 360.33M | 369.01M | 373.86M |
| SG&A Expenses | 106.71M | 103.32M | 99.27M | 97.34M | 94.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 556.38M | 550.26M | 541.01M | 535.96M | 526.55M |
| Operating Income | 163.50M | 173.04M | 181.67M | 194.70M | 205.42M |
| Income Before Tax | 123.62M | 135.67M | 161.84M | 172.75M | 189.19M |
| Income Tax Expenses | 25.53M | 24.04M | 27.13M | 31.12M | 29.67M |
| Earnings from Continuing Operations | 98.09 | 111.63 | 134.71 | 141.63 | 159.52 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 98.09M | 111.63M | 134.71M | 141.63M | 159.52M |
| EBIT | 163.50M | 173.04M | 181.67M | 194.70M | 205.42M |
| EBITDA | 220.20M | 228.83M | 236.73M | 248.30M | 258.39M |
| EPS Basic | 2.10 | 2.36 | 2.81 | 2.93 | 3.29 |
| Normalized Basic EPS | 1.96 | 2.10 | 2.11 | 2.23 | 2.44 |
| EPS Diluted | 2.03 | 2.26 | 2.67 | 2.76 | 3.06 |
| Normalized Diluted EPS | 1.91 | 2.02 | 2.01 | 2.10 | 2.27 |
| Average Basic Shares Outstanding | 186.97M | 189.04M | 191.19M | 193.14M | 193.72M |
| Average Diluted Shares Outstanding | 192.86M | 197.01M | 201.19M | 205.11M | 208.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |